查看2014.Doxorubicin.HSA的源代码

===  '''变量作为预后因素 (Variables as prognostic factors)''' === 

分析的与PFS和OS相关的变量分别列于表6/表S1，支持信息和表7/表S2。通过单因素分析，诊断时存在血小板减少症 （P =0.022） 且肿瘤大小大于中位数 （P =0.013） 或平均 （P =0.001） 最长直径与 PFS 降低显著相关。诊断时存在血小板减少症也与OS降低显著相关（P=0.034）。对于DOX治疗组的狗，诊断时存在转移与PFS（P = 0.591）或OS（P = 0.56）的降低没有显着相关性，尽管没有转移的治疗狗有更长寿的趋势。全分期（MST=114 d）、部分分期（MST=94 d）或无分期（MST=139 d）治疗犬组的OS差异无统计学意义，P=0.10。在接受同步节拍治疗的狗和未同时接受节拍疗法的狗之间没有发现 PFS 或 MST 的统计学差异。DOX剂量（30mg m-2 vs 1 mg kg-1）和给药频率（每2周与每3周一次）与PFS或OS无关。

Variables analysed for association with PFS and OS are presented in Table 6/Table S1, Supporting Information, and Table 7/Table S2, respectively. By univariate analysis, the presence of thrombocytopenia (P =0.022) at diagnosis and tumour size greater than the median (P =0.013) or mean (P =0.001) longest diameter were significantly associated with decreased PFS. The presence of thrombocytopenia at diagnosis was also significantly associated with decreased OS (P =0.034). For dogs in the DOX-treated group, the presence of metastasis at diagnosis was not significantly associated with decreased PFS (P =0.591) or OS (P =0.56), although there was a trend for treated dogs without metastasis to live longer. There was no significant difference in OS between groups of treated dogs that underwent full staging (MST=114 days), partial staging (MST=94 days),or no staging (MST=139 days), P =0.10. No statistical difference in PFS or MST was found between dogs receiving and those not receiving concurrent metronomic therapy. DOX dosage (30 mg m−2 versus 1 mg kg−1) and administration frequency (every 2 weeks versus every 3 weeks) were not associated with PFS or OS.